Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Homoharringtonine + Cytarabine in Newly Diagnosed AML
NCT05805098Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Started Mar 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05805098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805098.